_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
_256_384.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
Subscribe To Our Newsletter & Stay Updated
